Biopharmaceutical company Palatin Technologies Inc (NYSE American:PTN) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation for PL-8177 for the treatment of non-infectious intermediate, posterior, pan and chronic anterior uveitis.
Non-infectious uveitis is a group of inflammatory diseases that produce swelling and destroy eye tissue and can result in vision loss.
According to the company, PL-8177 is a selective MC1r (melanocortin receptor 1) agonist peptide and a synthetic cyclic heptapeptide with demonstrated efficacy in animal experimental autoimmune uveitis disease models. PL-8177 is a potent agonist at human MC1r, with sub-nanomolar affinity binding and EC50 functional values.
The company has launched a single and multiple ascending-dose Phase 1 study with PL-8177 under an investigational new drug (IND) application for ulcerative colitis. It plans to file an IND application for non-infectious uveitis with the FDA in the third quarter of calendar year 2019 as well as initiate a Phase 2 clinical study in the first half of calendar year 2020.
In both animal studies and Phase 1 subcutaneous studies with PL-8177, no safety or tolerability concerns were reported. PL-8177 has been evaluated in animal models of experimental autoimmune uveitis, a model presenting certain clinical features of human uveitis, the company said.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Halia Therapeutics collaborates with Canary Speech
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007
Sanofi reports FDA approval for Dupixent in paediatric EoE treatment